Related Experiment Video

Updated: Aug 22, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.0K

BCL-2 protein family: attractive targets for cancer therapy

Deeksha Kaloni1,2, Sarah T Diepstraten1, Andreas Strasser1,2

  • 1Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.

Apoptosis : an International Journal on Programmed Cell Death
|November 7, 2022
PubMed

Insights

Cancer cells evade apoptosis through BCL-2 family protein dysregulation. This review explores BCL-2 roles in cancer and BH3-mimetic drugs targeting pro-survival proteins for novel cancer therapies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Acquired resistance to cell death is a key characteristic of cancer.
  • The BCL-2 protein family regulates apoptotic cell death, and its dysregulation is common in malignancies.
  • Inhibition of apoptosis, due to altered BCL-2 family protein levels, contributes to cancer development and treatment resistance.

Purpose of the Study:

  • To review the roles of pro-survival and pro-apoptotic BCL-2 family proteins in normal physiology and cancer.
  • To discuss how defects in apoptosis control contribute to cancer progression and therapeutic resistance.
  • To examine the development of BH3-mimetic drugs targeting pro-survival BCL-2 proteins as a cancer treatment strategy.

Main Methods:

  • Literature review of BCL-2 protein family functions.
  • Analysis of the role of apoptosis regulation in cancer.
  • Discussion of therapeutic strategies targeting the BCL-2 pathway.

Main Results:

  • BCL-2 family proteins are critical regulators of apoptosis.
  • Dysregulation of these proteins promotes cancer development and resistance to therapy.
  • BH3-mimetic drugs are emerging as promising cancer therapeutics by inhibiting pro-survival BCL-2 proteins.

Conclusions:

  • Targeting the BCL-2 protein family offers a viable strategy for cancer treatment.
  • BH3-mimetic drugs represent a novel class of anti-cancer agents.
  • Understanding BCL-2 family dynamics is crucial for overcoming cancer therapy resistance.
Keywords:
ApoptosisBCL-2 protein familyBH3-mimetic drugsBH3-only proteinsPro-apoptotic BCL-2 family membersPro-survival BCL-2 proteins

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
Identifying Protein-protein Interaction Sites Using Peptide Arrays07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
638